NKGen Biotech (NASDAQ:NKGN) stock is rocketing higher on Thursday as the clinical-stage biotechnology company prepares to present new biomarker data on SNK01.
This is the company’s treatment candidate for Alzheimer’s disease. It’s going to provide this data to those attending the Alzheimer’s Association International Conference. This is set to take place from July 28 through Aug. 1.
The focus of the presentation will be on SNK01’s ability to reduce α-synuclein in Alzheimer’s patients. That’s important as α-synuclein has been tied to worse cognitive function for Alzheimer’s patients.
NKGen Biotech will hold its press conference on July 30. It will start at 7:30 a.m. Eastern. The event will end at 4:15 p.m. Eastern that same day. Hosting the event is company chairman and CEO Paul Song.
How This Affects NKGN Stock
NKGN stock is already up 17.7% as of Thursday morning alongside excitement for the upcoming presentation. This brings with it heavy trading with more than 33 million shares changing hands. That’s already well above its daily average trading volume of about 1.5 million shares.
It’s also possible that NKGN stock will see another rally alongside its presentation. That means investors will want to check back in on it when July 30 rolls around.
Here are more of the most recent stock market stories that traders need to know about on Thursday!
We are offering coverage of all of the latest stock market news for today! That includes what’s happening with shares of Agenus (NASDAQ:AGEN) stock, Lilium (NASDAQ:LILM) stock and Wayfair (NYSE:W) today. All of this news is ready at the links below!
More Thursday Stock Market News
- Why Is Agenus (AGEN) Stock Down 55% Today?
- LILM Stock Pops as Lilium Bags eVTOL Jet Order
- Dear Wayfair Stock Fans, Mark Your Calendars for July 26
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
